Invasive Versus Echocardiography-derived Transvalvular Gradients After TAVI Usign Balloon-expandable Transcatheter Heart Valves.
Launched by DEUTSCHES HERZZENTRUM MUENCHEN · Dec 22, 2024
Trial Information
Current as of June 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years and able to give consent
- • Severe symptomatic native aortic valve stenosis with indication for TAVI according to 2021 ESC/EACTS Valvular Heart Disease Guidelines.
- • Use of balloon-expandable THV
- • Written informed consent
- Exclusion Criteria:
- • Emergency or urgent treatment indication
- • Patients under hemodynamically unstable conditions.
- • Previous bioprosthetic aortic valve implantation
- • Patient cannot adhere to or complete the trial protocol for any reason
About Deutsches Herzzentrum Muenchen
Deutsches Herzzentrum München (German Heart Center Munich) is a leading institution in cardiovascular medicine, dedicated to advancing research, treatment, and education in heart health. Affiliated with the Technical University of Munich, the center specializes in innovative clinical trials aimed at improving diagnostic and therapeutic approaches for heart diseases. With a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to patient-centered care, Deutsches Herzzentrum München is at the forefront of developing novel interventions and enhancing clinical outcomes in cardiovascular health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Bayern, Germany
Patients applied
Trial Officials
Michael Joner, Professor Dr. med.
Study Director
Deutsches Herzzentrum München
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported